EValuate Ibrutinib Retention iN Chronic Lymphocytic Leukemia Patients Treated in a rEal World Setting - EVIdeNCE
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms EVIdeNCE
- Sponsors Janssen-Cilag
- 27 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2018 Status changed from not yet recruiting to recruiting.
- 31 Oct 2018 New trial record